Seoul St. Mary's Hospital

Ipsell, a biotech company, specializes in using induced pluripotent stem cells for cell lines, treatments, and platform services. Focusing on regenerative treatments for degenerative diseases, Ipsell aims to commercialize advanced stem cell therapies by 2030. Their cartilage regeneration treatment, MIUChon, has shown 30% improvement in joint indicators post-animal trial and is set for clinical trials. Ipsell has attracted over 30 billion won in investment and plans to administer the first patient dose early next year.